格隆汇3月29日丨东瑞制药(02348.HK)公告,集团截至2024年12月31日止年度录得收入约人民币10.6亿元,较2023年减少约7.9%。母公司拥有人应占溢利约人民币5.65亿元,比2023年增加约73.3%。母公司普通股权益持有人应占每股盈利0.3754元。董事会建议派发截至2024年12月31日止年度末期股息每股为港币0.048元(2023年:港币0.065元)。董事会建议派发截至...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.